The company delivered a convincing pair of beats in its third-quarter earnings report.
Teva Pharmaceutical Industries (TEVA +20.50%) had a day on the stock market to remember on Wednesday. The drugmaker‘s share price enjoyed a nearly 21% rise on the day, thanks mostly to a very well-received quarterly earnings report. That increase was far more powerful than the S&P 500 index’s 0.4% bump higher that trading session.
Powerful medicine
In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came from leading medications like Austedo, which improved its sales by 38% year over year to $618 million, and Ajovy, sales of which were up 19% to $168 million.
Image source: Getty Images.
As for the bottom line, Teva’s net income not according to generally accepted accounting principles (GAAP) rose far more robustly. It improved by 14% to $910 million, shaking out to $0.78 per share.
With those figures, Teva notched convincing beats over the average analyst forecasts. Prognosticators tracking the stock were collectively expecting it to post $4.36 billion for revenue and $0.68 per share for non-GAAP (adjusted) net profit.
Teva Pharmaceutical Industries
Today’s Change
(20.50%) $4.20
Current Price
$24.66
Key Data Points
Market Cap
$23B
Day’s Range
$22.72 – $25.00
52wk Range
$12.46 – $25.00
Volume
2.9M
Avg Vol
10M
Gross Margin
49.55%
Dividend Yield
N/A
Guidance tweaks
Teva also made some adjustments to its full-year 2025 guidance. It lowered the top end of its revenue estimate by $200 million; the range now stands at $16.8 billion to $17 billion. The company, however, left its net income forecast untouched — it remains at $2.55 to $2.65 per share for the year.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.